Study of CD10 expression pattern in prostatic adenocarcinoma and its correlation with Gleason's grade
DOI:
https://doi.org/10.37506/yhy69d08Keywords:
CD10, PROSTATIC ADENOCARCINOMA, Benign prostatic hyperplasia, Gleason grade group, PSAAbstract
Benign prostatic hyperplasia and carcinoma of the prostate are increasingly prevalent with advancing age. CD10, a 100-kDa transmembrane glycoprotein, plays a role in the cleavage and inactivation of specific peptide hormones essential for signal transduction. This zinc-dependent enzyme is widely expressed in the epithelial cells of the kidney, breast, lung, intestine, and prostate. The aim of our study is to evaluate the CD10 expression pattern in benign and malignant prostatic lesions by immunohistochemistry and to correlate it with Gleason grade group and pre-treatment PSA levels in prostatic adenocarcinoma.
Immunohistochemical staining for CD10 was performed on 56 cases of paraffin-embedded tissue from transurethral resected and core biopsy specimens of the prostate. Our study found that CD10 positivity was higher in prostatic adenocarcinoma patients compared to BPH patients, with a significant p-value of 0.003. Additionally, we identified a positive linear correlation between CD10 positivity and both Gleason grade group and PSA levels, with significant p-values of 0.0016 and 0.0083, respectively.
In conclusion, high CD10 expression may help accurately distinguish prostatic adenocarcinoma from BPH, thereby enhancing diagnostic accuracy.
References
Hariharan X, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol. 2016;32(2):103-108. doi:10.4103/0970-1591.174774.
Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, er a/. Global Cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012;367:248-57.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:S57-63.
Cerhan JR, Torner JC, Lynch CF, Rubensteln LM, Lemke JH, Cohen MB, et al. Association of smoking, body mass and physical activity with risk of prostate cancer in the Iowa 65+ Rural HealthStudy (United States). Cancer Causes Control 1997;8:229-38.
Alyson M, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007;16S:1271-9.
Platz EA, Yeole BB, Cho E, Jussawalla DJ, Giovannucci E, Ascherio A. Vasectomy and Prostate Cancer: A case - control study in India. Int J Epidemiol 1997;26:933-8.
Thompson IM, Pauler DX, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239A6.
Yu JB, Nakarov DV, Sharma R, Pesche RE, Partin AW, Gyoss CP. Validation of the Partin nomogram for prostatceancer in a national sample. J Urol. 2010; 183: 105-11.
Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defi ned by cell surface CD prof i Ie. Am J Pathol. 2004; 16S: 1543-56.
Erdds EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989; 3: 145-51.
Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003; 55: 71-80.
Osman I, Yee H, Taneja SS, et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004; 10: 4096-100.
DaIl’Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and iu clinical implication.BMC Urol. 2007; 7: 3.
Kaur M, Verma S, Gupta R, Pant L, Singh S. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades. Malays J Pathol. 2018 Apr;40(1):S7-60. PMID: 29704385.
Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 2;7:3. doi: 10.1186/1471-2490-7-3. PMID: 17335S64; PMCID: PMC1829163.
Fleischmann A, Schlomm T, Huland H, Kdllermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.11S8/1078-0432.CCR-08-1432. PMiD: 19047112.
Voutsadakis lA, Vlachostergios PJ, Daliani DD, Karasawidou F, Kakkas G, Moutzouris G, Melekos MD, Papandreou CN. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy. Urol Int. 2012;88(2):158-64. doi: 10.1159/000335299. Epub 2012 Jan 28. PMID: 22286396.
TawficS, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostatgeland. Hum Pathol. 2003 May;34(5):450-6.doi: 10.1016/s0046-8177(03)00077-7. PMIO: 12792918.
Singh,L., Marwah, N., Bhutani, N., Pawar, D., Kapil, R., Sen, R. Study the Expression of CD10 in Prostate Carcinomaand its Correlation with Various Clinicopathological Parameters. Iranian Journol of Pathology, 2019; 14(2):13S-141. doi: 10.30699/ijp.14.2.13S.
GlobaClancer Observatory : Cancer Today. Lyon, France: International Agency for Research on Cancer.Available from: https://gco.iarc.fr/today/accessed [16.01.2021].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Poulomi Biswas, Souvik Ghosh, Arundhati Shit
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.